These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18251495)

  • 1. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Li JJ; Nahra J; Johnson AR; Bunker A; O'Brien P; Yue WS; Ortwine DF; Man CF; Baragi V; Kilgore K; Dyer RD; Han HK
    J Med Chem; 2008 Feb; 51(4):835-41. PubMed ID: 18251495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
    Smaill JB; Gonzales AJ; Spicer JA; Lee H; Reed JE; Sexton K; Althaus IW; Zhu T; Black SL; Blaser A; Denny WA; Ellis PA; Fakhoury S; Harvey PJ; Hook K; McCarthy FO; Palmer BD; Rivault F; Schlosser K; Ellis T; Thompson AM; Trachet E; Winters RT; Tecle H; Bridges A
    J Med Chem; 2016 Sep; 59(17):8103-24. PubMed ID: 27491023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists.
    Storelli S; Verzijl D; Al-Badie J; Elders N; Bosch L; Timmerman H; Smit MJ; De Esch IJ; Leurs R
    Arch Pharm (Weinheim); 2007 Jun; 340(6):281-91. PubMed ID: 17562560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines.
    Hafez HN; Abbas HA; El-Gazzar AR
    Acta Pharm; 2008 Dec; 58(4):359-78. PubMed ID: 19103572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
    Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.
    Didiuk MT; Griffith DA; Benbow JW; Liu KK; Walker DP; Bi FC; Morris J; Guzman-Perez A; Gao H; Bechle BM; Kelley RM; Yang X; Dirico K; Ahmed S; Hungerford W; DiBrinno J; Zawistoski MP; Bagley SW; Li J; Zeng Y; Santucci S; Oliver R; Corbett M; Olson T; Chen C; Li M; Paralkar VM; Riccardi KA; Healy DR; Kalgutkar AS; Maurer TS; Nguyen HT; Frederick KS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4555-9. PubMed ID: 19625189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
    Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H
    J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity.
    La Motta C; Sartini S; Mugnaini L; Simorini F; Taliani S; Salerno S; Marini AM; Da Settimo F; Lavecchia A; Novellino E; Cantore M; Failli P; Ciuffi M
    J Med Chem; 2007 Oct; 50(20):4917-27. PubMed ID: 17845019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
    Hanrahan P; Bell J; Bottomley G; Bradley S; Clarke P; Curtis E; Davis S; Dawson G; Horswill J; Keily J; Moore G; Rasamison C; Bloxham J
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2271-8. PubMed ID: 22342626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation.
    Tu S; Zhang J; Zhu X; Xu J; Zhang Y; Wang Q; Jia R; Jiang B; Zhang J
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3578-81. PubMed ID: 16621547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
    Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
    J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrido[2,3-d]pyrimidine angiotensin II antagonists.
    Ellingboe JW; Antane M; Nguyen TT; Collini MD; Antane S; Bender R; Hartupee D; White V; McCallum J; Park CH
    J Med Chem; 1994 Feb; 37(4):542-50. PubMed ID: 8120871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
    Liverton NJ; Bednar RA; Bednar B; Butcher JW; Claiborne CF; Claremon DA; Cunningham M; DiLella AG; Gaul SL; Libby BE; Lyle EA; Lynch JJ; McCauley JA; Mosser SD; Nguyen KT; Stump GL; Sun H; Wang H; Yergey J; Koblan KS
    J Med Chem; 2007 Feb; 50(4):807-19. PubMed ID: 17249648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific enzyme inhibitors in vitamin biosynthesis. II. Revised structures for some 8-substituted pyrido(2,3-d)pyrimidines.
    Wood HC; Wrigglesworth R; Yeowell DA; Gurney FW
    J Chem Soc Perkin 1; 1974; 11(0):1225-30. PubMed ID: 4859484
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors.
    Matulenko MA; Lee CH; Jiang M; Frey RR; Cowart MD; Bayburt EK; Didomenico S; Gfesser GA; Gomtsyan A; Zheng GZ; McKie JA; Stewart AO; Yu H; Kohlhaas KL; Alexander KM; McGaraughty S; Wismer CT; Mikusa J; Marsh KC; Snyder RD; Diehl MS; Kowaluk EA; Jarvis MF; Bhagwat SS
    Bioorg Med Chem; 2005 Jun; 13(11):3705-20. PubMed ID: 15863000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.